BPC-157 Dosage Guide: Oral vs Injection Dosing, Timing, and Cycle Protocol (2026)

Key Takeaways

• Injectable BPC-157 is typically dosed at 200–500 mcg per day, either as a single injection or split into two doses.
• Oral BPC-157 requires higher doses — generally 500–1,000 mcg daily — due to lower systemic bioavailability, but is the preferred route for gut-specific benefits.
• For acute injuries, a 2–4 week cycle is often sufficient; chronic conditions may require 4–8 weeks with a break before repeating.
• Timing matters: injections are generally most effective on an empty stomach, and splitting doses throughout the day can maintain more stable tissue levels.
• Reconstitution errors are the most common beginner mistake — always use the Peptide Calculator to verify your dilution math before drawing your first dose.

BPC-157 dosing is one of those topics where the internet gives you ten different answers and somehow leaves you more confused than when you started. You’ll find forum posts recommending 200 mcg, others insisting 500 mcg is the minimum to feel anything, some people swearing by multiple daily injections, and others taking it orally once a day with no injections at all.

Here’s the reality: the “right” BPC-157 dose and administration method genuinely depends on what you’re trying to accomplish. The dosing strategy for healing a torn Achilles tendon looks different from the protocol for repairing a leaky gut, which looks different again from a general systemic anti-inflammatory approach.

This guide is designed to give you a thorough, practical understanding of BPC-157 dosing across every relevant variable — injection vs. oral, local vs. systemic, acute vs. chronic conditions, and timing strategies that actually matter. By the end, you’ll have everything you need to build or evaluate a protocol that’s dialed in for your specific situation.

What Is BPC-157?

Before getting into dosing specifics, it’s worth grounding ourselves in what BPC-157 actually is, because that context shapes everything about how and why you’d dose it a particular way.

BPC-157 — Body Protection Compound 157 — is a pentadecapeptide: a synthetic peptide consisting of 15 amino acids. It was derived from a naturally occurring protective protein found in human gastric juice, where researchers observed that certain peptide fragments appeared to have remarkable cytoprotective (cell-protecting) properties. The “157” in the name refers to the specific fragment sequence isolated from that gastric protein.

What makes BPC-157 particularly compelling in research contexts is its apparent pleiotropic activity — it doesn’t work through a single, narrow pathway. Instead, it operates across multiple mechanisms: it promotes angiogenesis (new blood vessel formation), upregulates growth hormone receptor expression, modulates nitric oxide synthesis, interacts with the dopaminergic and serotonergic neurotransmitter systems, and exerts anti-inflammatory effects across various tissue types.

This multi-pathway activity explains both its versatility and why it’s so widely discussed — it can be beneficial for tendon and ligament injuries, muscle strains, GI tract conditions, joint inflammation, and even neurological applications. It also means that the optimal dosing approach shifts based on the target tissue and condition, which is the core theme of this entire guide.

For a complete biochemical profile and full literature overview, visit the BPC-157 entry in our Peptide Database.

Injectable BPC-157 Dosing

Subcutaneous injection is widely considered the most efficient systemic delivery method for BPC-157. When injected, the peptide bypasses the digestive system and enters circulation more directly, leading to higher bioavailability compared to oral administration.

Standard Dose Range

The most commonly referenced dosing range in research contexts is 200 to 500 mcg per day. Most users and researchers work within this window, with the majority landing around 250–300 mcg daily as a practical starting point.

A few important nuances here:

• Lower end (200 mcg/day): Appropriate for general systemic benefits, mild GI support, or as a maintenance dose during recovery. Some users find this sufficient for ongoing low-grade inflammation.
• Mid-range (250–350 mcg/day): The most common working range. Effective for most injury applications while remaining conservative from a dosing standpoint.
• Higher end (400–500 mcg/day): Often used for acute, significant injuries — severe tendon damage, post-surgical healing, or chronic inflammatory conditions that haven’t responded to lower doses.

Single vs. Split Dosing

BPC-157 has a relatively short half-life of approximately 4 hours when administered via injection. This creates a meaningful question: is it better to take one larger daily dose or split it into two smaller doses?

The honest answer is that the research doesn’t give a definitive verdict, but practical considerations favor splitting the dose when your target is sustained tissue levels. Two injections of 125–200 mcg taken 8–12 hours apart maintain more consistent plasma concentrations than a single bolus dose that peaks and then falls off.

For convenience-driven protocols or when the priority is simplicity (especially for beginners), a single daily injection is entirely reasonable and still produces results.

Local vs. Systemic Injection

This is one of the most important — and most frequently misunderstood — aspects of injectable BPC-157 dosing.

Local injection means injecting subcutaneously near the injured tissue. If you have a knee injury, you’d inject near (not into) the knee. If it’s a shoulder issue, you’d inject near the shoulder. The idea is that local administration concentrates the peptide’s activity near the target site.

Systemic injection — typically into abdominal fat — delivers BPC-157 into general circulation where it distributes throughout the body. This is the standard approach for GI benefits, full-body inflammation, or when local injection isn’t practical.

The emerging consensus based on animal research and widespread anecdotal reports is that BPC-157 is effective both locally and systemically. For localized injuries (tendon, ligament, specific joint), local injection may accelerate healing at that specific site more efficiently. For systemic goals, abdominal injection is more convenient and still produces robust effects.

Many experienced users do both — a local injection near the injury site and a second systemic injection — when dealing with significant acute injuries.

Oral BPC-157 Dosing

BPC-157 can also be taken orally, typically in capsule form, and this route has a dedicated following — particularly among people whose primary interest is gastrointestinal health. Given that BPC-157 was originally derived from a gastric protein, there’s a certain logic to delivering it directly to the GI tract.

Why Oral Bioavailability Is Different

When BPC-157 is swallowed, it passes through the digestive system before reaching systemic circulation. Some of it is broken down by digestive enzymes and stomach acid before it can be absorbed. This doesn’t mean oral BPC-157 doesn’t work — it clearly does for many people — but it does mean that you need a higher dose to achieve equivalent systemic levels compared to injectable administration.

For GI-specific applications, however, this isn’t a disadvantage at all. Higher concentrations in the GI tract during transit is exactly what you want when the target is intestinal healing, ulcer repair, or reducing gut permeability.

Oral Dose Range

Common oral dosing ranges sit between 500 and 1,000 mcg per day, with many users reporting optimal results around 600–800 mcg. This is roughly 2–4 times the injectable dose to account for reduced bioavailability.

For purely gut-focused applications, some researchers and practitioners use doses at the higher end of this range (800–1,000 mcg) to ensure sufficient local concentration throughout the entire GI tract.

Oral BPC-157 for Systemic Goals

If your goal is systemic effects — healing a shoulder injury, recovering from a muscle strain, or general anti-inflammatory support — oral BPC-157 is considered less efficient than injection. You can still achieve systemic effects, but the dose requirements are higher and the consistency of absorption is more variable.

The practical implication: for non-GI goals, injection is worth learning to do properly. For GI goals (IBD, IBS, leaky gut, gastric ulcers, esophageal issues), oral capsules are often the preferred and more logical choice.

Injectable vs. Oral — Which Route Is Better?

The answer depends entirely on your primary goal. Here’s a direct comparison:

The pragmatic answer: If you’re comfortable with injections and your goal is musculoskeletal recovery or systemic inflammation, injectable is the more efficient choice. If you have a gut condition or you’re firmly opposed to injections, oral is genuinely effective for appropriate use cases and worth pursuing.

Some users do both simultaneously — oral capsules for ongoing gut support, plus periodic injectable cycles for injury management.

BPC-157 Cycle Length and Protocol

One of the most common questions around BPC-157 is how long to run it and whether you need to cycle off. The answer depends significantly on whether you’re dealing with an acute injury, a chronic condition, or using it for general maintenance.

Acute Injury Protocol (2–4 Weeks)

For fresh injuries — a recent tendon strain, a muscle pull, post-surgical healing — a relatively short cycle is often sufficient to observe meaningful benefit. The typical approach:

• Duration: 2–4 weeks of daily use
• Dose: 250–400 mcg/day (injectable), split or single dose
• Administration: Local injection near injury site if feasible, systemic otherwise
• Post-cycle: Assess healing progress; repeat cycle if needed after a 2–4 week break

Chronic Condition Protocol (4–8 Weeks)

For chronic injuries — long-standing tendinopathy, persistent joint inflammation, recurring gut issues — a longer cycle allows time for cumulative tissue remodeling to take effect:

• Duration: 4–8 weeks of daily use
• Dose: 200–350 mcg/day (injectable) or 500–800 mcg/day (oral for GI)
• Post-cycle: Mandatory 4–6 week break before repeating
• Long-term strategy: Many users run 2–3 cycles per year for chronic conditions

Should You Cycle BPC-157?

BPC-157 does not appear to cause hormonal suppression or receptor downregulation based on available research, which means the case for strict cycling isn’t as strong as it is for hormonal peptides. That said, cycling on and off remains a widely recommended approach for practical reasons:

• It allows you to assess whether the peptide is still producing meaningful benefit
• It prevents reliance on any exogenous compound for ongoing tissue health
• The available research is still developing, and conservative cycling is a prudent approach given the incomplete human data

Timing Your Doses

Timing is one of those variables that gets less attention than it deserves. While BPC-157 doesn’t have the same rigid timing requirements as growth hormone secretagogues (which need to be taken in a fasted state), timing still matters.

Empty Stomach vs. Fed State

For injectable BPC-157, taking it on an empty stomach appears to produce faster absorption, though the practical difference is modest. Most protocols don’t require strict fasting before injection.

For oral BPC-157, the evidence and anecdotal consensus lean toward taking it on an empty stomach — either first thing in the morning or between meals — to minimize competition from food-related digestive activity and potentially improve GI transit to the target areas.

Morning vs. Evening Dosing

There’s no strong evidence that morning or evening is universally superior for BPC-157. Some considerations:

• Morning dosing works well for maintaining a consistent schedule and is practical for single daily injections.
• Evening dosing is sometimes preferred because much of the body’s repair activity occurs during sleep, potentially allowing BPC-157 to work alongside natural overnight healing processes.
• Split dosing (morning and evening) covers both windows and maintains more stable plasma levels throughout the day.

Splitting Doses for Injury Recovery

Given BPC-157’s ~4 hour half-life via injection, a split dosing approach — say 200 mcg in the morning and 200 mcg in the evening — keeps the peptide more consistently present in circulation. This is particularly relevant for acute injury recovery, where sustained tissue exposure may accelerate healing compared to a single daily peak.

Reconstitution and Preparation

BPC-157 is typically sold as a lyophilized (freeze-dried) powder in sterile vials. Before it can be injected, it must be reconstituted with bacteriostatic water (BAC water). This process is straightforward once you understand it, but getting the math right is critical — an error here means every dose you draw will be off.

The Basic Reconstitution Process

1. Wipe the top of the peptide vial and BAC water vial with an alcohol swab and allow to dry.
2. Draw the desired volume of BAC water into your syringe.
3. Insert the needle into the peptide vial and slowly inject the water down the side of the vial — do not spray directly onto the powder.
4. Gently swirl (do not shake) until the powder fully dissolves into a clear solution.
5. Store reconstituted solution in the refrigerator (2–8°C). Use within 28–30 days.

How Much BAC Water to Use

This depends on your vial size and target dose, and this is exactly where math errors happen. The most common vials contain 5 mg (5,000 mcg) of BPC-157. Here’s a simple example:

• 5 mg vial + 2 mL BAC water = 2,500 mcg per mL, or 250 mcg per 0.1 mL (10 units on an insulin syringe)
• 5 mg vial + 2.5 mL BAC water = 2,000 mcg per mL, or 200 mcg per 0.1 mL

Rather than doing this manually and risking errors, use the Peptide Reconstitution Calculator on PeptidesHelper to get your exact dilution and draw volume. Enter your vial size, BAC water volume, and target dose — the calculator handles the rest.

Equipment You’ll Need

• Bacteriostatic water (BAC water, not sterile water)
• Insulin syringes (typically 1 mL, 29–31 gauge)
• Alcohol swabs
• A refrigerator for storage
• A sharps disposal container

Common Dosing Mistakes

Even with solid information, certain mistakes come up repeatedly. Here are the most consequential ones to avoid:

1. Underdosing the Oral Form

This is extremely common. People familiar with injectable dosing try to translate those doses directly to oral use, taking 200–300 mcg orally and wondering why they’re not seeing results. The oral form requires significantly higher doses — at minimum 500 mcg, often 600–800 mcg — to produce meaningful systemic effects. For GI-specific goals, some protocols use up to 1,000 mcg daily.

2. Injecting at the Wrong Site for Local Injury

If you have a specific injury you’re trying to target locally, injecting in your abdomen for convenience still produces systemic effects — but you may miss some of the enhanced local concentration benefit. For knee injuries, inject near the knee. For shoulder injuries, inject near the shoulder. You don’t need to inject into the joint itself (that’s a different procedure entirely), but subcutaneous injection in the general area of the injury is the approach used in most relevant studies.

3. Running Too Short a Cycle for Chronic Conditions

A 2-week cycle can produce noticeable results for acute, fresh injuries. For chronic tendinopathy, persistent gut issues, or long-standing inflammation, 2 weeks is often not enough time for the cumulative tissue remodeling effects to manifest. Be patient and commit to a full 4–8 week cycle for chronic conditions before evaluating results.

4. Skipping Cycling Entirely

BPC-157 may not cause the hormonal suppression that some peptides do, but running it indefinitely without breaks isn’t recommended. Take breaks between cycles, assess your baseline between runs, and don’t use peptides as a substitute for addressing the root causes of chronic injury patterns.

5. Reconstitution Math Errors

As covered above, this is arguably the most impactful beginner mistake. Drawing 0.1 mL from a vial reconstituted at the wrong ratio means you’re either significantly underdosing or overdosing. Always calculate this before your first injection using the Peptide Calculator.

6. Using Sterile Water Instead of Bacteriostatic Water

Sterile water does not contain the benzyl alcohol preservative that bacteriostatic water does. Reconstituting with sterile water means your solution will have a much shorter shelf life (typically 24 hours vs. 28–30 days for BAC water). Always use bacteriostatic water unless your protocol specifically calls for something else.

7. Storing Reconstituted Peptide Incorrectly

The reconstituted solution should be kept in the refrigerator at 2–8°C. Freezing the liquid solution can disrupt the peptide structure. Room temperature storage significantly accelerates degradation. Lyophilized powder, on the other hand, can often be stored frozen for longer-term preservation before reconstitution.

Frequently Asked Questions

What is the best BPC-157 dosage for a tendon injury?

For acute tendon injuries, most protocols call for 250–400 mcg per day via subcutaneous injection, ideally with at least one injection administered near the injury site. A 4–6 week cycle is standard for tendon applications. Split dosing (e.g., 200 mcg morning and 200 mcg evening) may maintain more consistent tissue-level concentrations. Use the Peptide Calculator to confirm your reconstitution math before drawing your first dose.

Can I take BPC-157 orally for a gut issue and inject for a separate injury at the same time?

Yes, this is a legitimate approach and some users do exactly this. Oral BPC-157 delivers higher concentrations to the GI tract for gut-specific healing, while a separate injectable protocol addresses musculoskeletal repair systemically. Keep in mind that you are administering BPC-157 through two routes simultaneously, so monitor your total daily dose and be attentive to how you feel. There’s no known interaction risk between the two forms, but as always, this should be approached under informed guidance.

How long does it take for BPC-157 to work?

Timeline varies by condition severity and individual response. For acute soft tissue injuries with injectable BPC-157, many users notice meaningful improvement in pain and function within 7–14 days. For tendon and ligament repair, the structural healing process takes longer — expect 3–6 weeks for significant improvement. GI benefits via oral BPC-157 can sometimes be felt within the first week. Chronic conditions generally require the full 4–8 week cycle to evaluate meaningfully.

Is BPC-157 safe for long-term use?

The available research does not indicate significant toxicity or safety concerns at standard research doses in animal models. However, long-term human safety data remains limited. For this reason, most protocols recommend cycling BPC-157 rather than continuous indefinite use. If considering extended or repeated use, working with a healthcare provider who is familiar with peptide therapy is strongly advisable.

What’s the difference between BPC-157 and BPC-157 Arginate (BPC-157 Stable)?

BPC-157 Arginate (sometimes called BPC-157 Stable or BPC-157a) is a salt form of BPC-157 that is more stable at room temperature and in acidic environments. This makes it particularly advantageous for oral administration, where standard BPC-157 faces degradation from stomach acid. Some researchers believe BPC-157 Arginate offers improved oral bioavailability. For injectable use, standard BPC-157 remains the more commonly used and studied form.

Can I use BPC-157 while taking prescription medications?

This is a question that must be answered by a qualified healthcare provider who knows your specific medication regimen. BPC-157 interacts with dopaminergic and serotonergic systems in ways that could theoretically be relevant for people taking psychiatric medications. Its effects on nitric oxide pathways may also be relevant for certain cardiovascular medications. Do not assume that “peptide” equals “safe with everything” — get proper medical guidance before combining BPC-157 with prescription drugs.

Do I need a prescription for BPC-157?

The regulatory status of BPC-157 varies by country. In the United States, BPC-157 is classified as a research compound and is not approved by the FDA for human therapeutic use. It is not a scheduled substance, but it is also not legally available as a human drug. The regulatory landscape for research peptides continues to evolve, so always check current regulations in your jurisdiction. Visit our Peptide Database for up-to-date regulatory notes on BPC-157 and other research peptides.

Disclaimer: The information presented in this article is for research and educational purposes only. BPC-157 is a research compound that has not been approved by the FDA or any equivalent regulatory agency for human therapeutic use. Nothing contained in this guide constitutes medical advice, diagnosis, or a treatment recommendation. Individual results vary, and using peptides carries risks that should be carefully considered. Always consult a licensed and qualified healthcare professional before beginning any peptide protocol, particularly if you have existing health conditions, are taking prescription medications, or are pregnant or breastfeeding. Use all research compounds in accordance with applicable laws and regulations in your jurisdiction.